Evidence map›Paper›PMID 32283413›Full record

ReviewPhytomedicine : international journal of phytotherapy and phytopharmacology2020

Adjuvant herbal therapy for targeting susceptibility genes to Kawasaki disease: An overview of epidemiology, pathogenesis, diagnosis and pharmacological treatment of Kawasaki disease.

Bin Tang, Hang Hong Lo, Cheng Lei, Ka In U, Wen-Luan Wendy Hsiao, Xiaoling Guo, Jun Bai, Vincent Kam-Wai Wong, Betty Yuen-Kwan Law

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Phytomedicine : international journal of phytotherapy and phytopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Bin TangState Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China.
Hang Hong LoState Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China.
Cheng LeiDepartment of Pediatrics, Kiang Wu Hospital, Macau SAR, China.
Ka In UDepartment of Pediatrics, Kiang Wu Hospital, Macau SAR, China.
Wen-Luan Wendy HsiaoState Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China.
Xiaoling GuoSouth Medical University Affiliated Maternal & Child Health Hospital of Foshan, Foshan, China.
Jun BaiSouth Medical University Affiliated Maternal & Child Health Hospital of Foshan, Foshan, China.
Vincent Kam-Wai WongState Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China.
Betty Yuen-Kwan LawState Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China.
Macau University of Science and Technology · MOFoshan Maternity and Child Health Care Hospital · CNKiang Wu Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKawasaki disease (KD) is a self-limiting acute systemic vasculitis occur mainly in infants and young children under 5 years old. Although the use of acetylsalicylic acid (AAS) in combination with intravenous immunoglobulin (IVIG) remains the standard therapy to KD, the etiology, genetic susceptibility genes and pathogenic factors of KD are still un-elucidated. PURPOSE: Current obstacles in the treatment of KD include the lack of standard clinical and genetic markers for early diagnosis, possible severe side effect of AAS (Reye's syndrome), and the refractory KD cases with resistance to IVIG therapy, therefore, this review has focused on introducing the current advances in the identification of genetic susceptibility genes, environmental factors, diagnostic markers and adjuvant pharmacological intervention for KD.

resultsWith an overall update in the development of KD from different aspects, our current bioinformatics data has suggested CASP3, CD40 and TLR4 as the possible pathogenic factors or diagnostic markers of KD. Besides, a list of herbal medicines which may work as the adjunct therapy for KD via targeting different proposed molecular targets of KD have also been summarized.

conclusionWith the aid of modern pharmacological research and technology, it is anticipated that novel therapeutic remedies, especially active herbal chemicals targeting precise clinical markers of KD could be developed for accurate diagnosis and treatment of the disease.

Indexed as

Adjuvants, ImmunologicAdjuvants, PharmaceuticAspirinCaspase 3CD40 AntigensChildChild, PreschoolGenetic MarkersGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansImmunoglobulins, IntravenousInfantJapanMucocutaneous Lymph Node SyndromePhytotherapyAdjuvants, ImmunologicAdjuvants, PharmaceuticAspirinCASP3 protein, humanCaspase 3CD40 AntigensGenetic MarkersImmunoglobulins, IntravenousTLR4 protein, humanToll-Like Receptor 4AAS, acetylsalicylic acidAdjuvant therapyAHA, the American Heart AssociationCALs, coronary artery lesionsCASP, caspaseCD, cluster of differentiationC IVIG, intravenous immunoglobulinCRP, C-reactive proteinDAVID, Database for Annotation, Visualization and Integrated DiscoveryDiagnostic markerEpidemiologyFCGR2A, Fc fragment of immunoglobulin G, low-affinity IIaGWAS, genome-wide association methodHAdV, the human adenovirusHerbal chemicalsIL, InterleukinITPKC, inositol 1,4,5-triphosphate 3-kinaseKawasaki diseaseKD, Kawasaki diseaseMyD88, myeloid differentiation factor 88NF-κB, nuclear factor κBRS, Reye's syndromeSNPs, single nucleotide polymorphismsSusceptibility genesTCMs, traditional Chinese medicinesTh, T helperTLR4, toll-like receptor 4TNF, tumor necrosis factor

Identifiers

PMID32283413
PMCPMC7118492
OpenAlexW3011866642

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.